Actuate Therapeutics Inc (ACTU) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.5x

Market Cap

$35.54M

MomentumView details →

1D Return

+8.03%

YTD Return

−76.51%

RSI (14)

53.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.5x

Market Cap

$35.54M

RSI (14)

53.3

MomentumView details →

1D Return

+8.03%

YTD Return

−76.51%

SummaryUpdated Jun 1, 2026

Actuate Therapeutics Inc (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company founded in 2015 and based in Fort Worth, Texas. Originally incorporated as Apotheca Therapeutics, the company changed its name to Actuate Therapeutics in October 2015. The company went public in August 2024 and focuses on developing novel cancer therapies, with its lead product candidate being a glycogen synthase kinase-3 inhibitor for treating various forms of cancer including pancreatic, colorectal, and rare cancers.

Ask drillr about Actuate Therapeutics Inc →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−2067.81%

ROA (TTM)

−393.39%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+49.72%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+67.48%

EBITDA YoY

+16.58%

EarningsView details →

EPS (Actual)

−$0.20

EPS Surprise

4.76%

Beats (12Q)

3/12

Next Q EPS Est

−$0.17

Avg Surprise (4Q)

8.21%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.41x

Current Ratio

1.25x

Quick Ratio

1.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−20.45M

Op. CF (TTM)

−19.84M

Next earningsNov 12, 2026 →

Latest newsMore news →

No recent news for ACTU.

Similar companies

NextCure, Inc.NXTC TransCode Therapeutics, Inc.RNAZ Elutia Inc.ELUT Context Therapeutics Inc.CNTX CervoMed Inc.CRVO Aligos Therapeutics, Inc.ALGS Find similar companies →

Latest newsMore news →

No recent news for ACTU.